In vivo and in vitro estrogenic and progestagenic actions of Tibolone
Estrogen and progestin combination in hormone replacement therapy (HRT) increases the incidence of breast cancer, but decreases the endometrial cancer risk of unopposed estrogen. Therefore, a SERM such as Tibolone, that delivers the beneficial, but not the adverse side effects, of steroid hormones w...
Enregistré dans:
| Auteurs principaux: | SADARANGANI,ANIL, SALGADO,ANA MARÍA, KATO,SUMIE, PINTO,MAURICIO, CARVAJAL,ANDRÉS, MONSO,CAROLINA, OWEN,GARETH I, VIGIL,PILAR |
|---|---|
| Langue: | English |
| Publié: |
Sociedad de Biología de Chile
2005
|
| Sujets: | |
| Accès en ligne: | http://www.scielo.cl/scielo.php?script=sci_arttext&pid=S0716-97602005000200014 |
| Tags: |
Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!
|
Documents similaires
-
The action of ovarian hormones in cardiovascular disease
par: MEDINA,RODOLFO A, et autres
Publié: (2003) -
Efecto diferencial sobre el IGF-1 sérico de tibolona (5 mg/día) vs combinado continuo de estrógeno/progestina en mujeres postmenopáusicas
par: Porcile,Arnaldo, et autres
Publié: (2003) -
Comparative safety and efficacy of tibolone and escitalopram in postmenopausal women
par: Rajnish Raj, et autres
Publié: (2021) -
Solving the Puzzle: What Is the Role of Progestogens in Neovascularization?
par: Zhi Xia, et autres
Publié: (2021) -
Survival rates of advanced estrogen-receptor positive breast cancer. Analysis of 211 cases
par: Sánchez,César, et autres
Publié: (2020)